User profiles for J. Cloos
Jacqueline CloosResearch coordinator, Hematology, VU University Medical Center, Verified email at vumc.nl Cited by 15815 |
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
…, MC Béné, F Buccisano, J Cloos… - Blood, The Journal …, 2018 - ashpublications.org
Measurable residual disease (MRD; previously termed minimal residual disease) is an
independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is …
independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is …
[HTML][HTML] The role of alternative splicing in cancer: From oncogenesis to drug resistance
…, G Jansen, GJL Kaspers, E Giovannetti, J Cloos - Drug Resistance …, 2020 - Elsevier
Alternative splicing is a tightly regulated process whereby non-coding sequences of pre-mRNA
are removed and protein-coding segments are assembled in diverse combinations, …
are removed and protein-coding segments are assembled in diverse combinations, …
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
…, YG Assaraf, S Zweegman, GJL Kaspers, J Cloos - Drug resistance …, 2015 - Elsevier
Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a
cornerstone position in the treatment of hematological malignancies, particularly multiple …
cornerstone position in the treatment of hematological malignancies, particularly multiple …
Cell sensitivity assays: the MTT assay
J Van Meerloo, GJL Kaspers, J Cloos - Cancer cell culture: methods and …, 2011 - Springer
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay is based on
the conversion of MTT into formazan crystals by living cells, which determines mitochondrial …
the conversion of MTT into formazan crystals by living cells, which determines mitochondrial …
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML)
that is used for prognostic, predictive, monitoring, and efficacy-response assessments. …
that is used for prognostic, predictive, monitoring, and efficacy-response assessments. …
[HTML][HTML] Molecular minimal residual disease in acute myeloid leukemia
…, PL Gradowska, R Meijer, J Cloos… - … England Journal of …, 2018 - Mass Medical Soc
Background Patients with acute myeloid leukemia (AML) often reach complete remission, but
relapse rates remain high. Next-generation sequencing enables the detection of molecular …
relapse rates remain high. Next-generation sequencing enables the detection of molecular …
[HTML][HTML] Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features
Background Medulloblastoma is the most common malignant brain tumor in children.
Despite recent improvements in cure rates, prediction of disease outcome remains a major …
Despite recent improvements in cure rates, prediction of disease outcome remains a major …
Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
…, NE Franke, YG Assaraf, J Cloos… - Blood, The Journal …, 2008 - ashpublications.org
The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in
the treatment of refractory multiple myeloma. However, its clinical efficacy has been …
the treatment of refractory multiple myeloma. However, its clinical efficacy has been …
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia
…, I Wlodarska, B Cauwelier, J Cloos, J Soulier… - Nature …, 2013 - nature.com
T-cell acute lymphoblastic leukemia (T-ALL) is caused by the cooperation of multiple
oncogenic lesions 1 , 2 . We used exome sequencing on 67 T-ALLs to gain insight into the …
oncogenic lesions 1 , 2 . We used exome sequencing on 67 T-ALLs to gain insight into the …
[PDF][PDF] In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma
Kinases execute pivotal cellular functions and are therefore widely investigated as potential
targets in anticancer treatment. Here we analyze the kinase gene expression profiles of …
targets in anticancer treatment. Here we analyze the kinase gene expression profiles of …